Detalhe da pesquisa
1.
Comparison of major adverse event rates after elective endovascular aneurysm repair in New England using a novel measure of complication severity.
J Vasc Surg
; 70(1): 74-79, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30598356
2.
Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Cancer Immunol Immunother
; 67(10): 1519-1531, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30039427
3.
CAR T cells: driving the road from the laboratory to the clinic.
Immunol Rev
; 257(1): 91-106, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24329792
4.
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Cancer Immunol Immunother
; 66(11): 1425-1436, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28660319
5.
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Lancet Oncol
; 17(3): 378-388, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26794930
6.
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.
J Immunol
; 192(8): 3654-65, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24623129
7.
Overcoming the toxicity hurdles of genetically targeted T cells.
Cancer Immunol Immunother
; 64(1): 123-30, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25488419
8.
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Cancer Immunol Immunother
; 63(2): 133-45, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24190544
9.
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Oncology
; 87(6): 342-50, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25227656
10.
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.
J Clin Oncol
; 41(11): 1957-1964, 2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37018920
11.
Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.
Front Immunol
; 14: 1256491, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38022678
12.
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Cancer Immunol Immunother
; 61(7): 953-62, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22527245
13.
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.
J Immunol
; 184(12): 6938-49, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20483753
14.
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
J Immunol
; 184(4): 1885-96, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20089697
15.
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Am J Cancer Res
; 12(8): 3967-3984, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36119832
16.
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs.
Clin Immunol
; 140(3): 218-22, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21570917
17.
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Clin Immunol
; 138(1): 85-96, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21056008
18.
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Cancer Immunol Immunother
; 60(6): 829-37, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21387109
19.
Gene delivery of a mutant TGFß3 reduces markers of scar tissue formation after cutaneous wounding.
Mol Ther
; 18(12): 2104-11, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20736928
20.
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
Kidney Cancer J
; 19(3): 64-72, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34765076